免疫関連有害事象irAEマネジメント　膠原病科医の視点から

第3部

P.505 掲載の参考文献

Gozokan HN, et al. Acquired hemophilia A after nivolumab therapy in a patient with metastatic squamous cell carcinoma of the lung successfully managed with rituximab. Clin Lung Cancer. 2019 ; 20 : e560-e563. PMID : 31311716

 

P.506 掲載の参考文献

Bossart S, et al. Case report : Encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist. 2017 ; 22 : 749-753. PMID : 28559410

 

P.508 掲載の参考文献

Alessandro C, et al. Immune checkpoint inhibitor-related cytokine release syndrome : analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020 ; 11 : 557. PMID : 32425791

 

Ohira J, et al. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore). 2020 ; 99 : e19741. PMID : 32282733

 

P.510 掲載の参考文献

Arnouk J, et al. A celiac disease phenotype after checkpoint Inhibitor exposure : an example of immune dysregulation after immunotherapy. ACG Case Rep J. 2019 ; 6 : e00158. PMID : 31737699

 

Alsaadi D, et al. A case of checkpoint inhibitor-induced celiac disease. J Immunother Cancer. 2019 ; 7 : 203. PMID : 31383006

 

P.511 掲載の参考文献

Kosche C, et al. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma : a case report and review of the literature. Melanoma Res. 2020 ; 30 : 313-316. PMID : 31567590

 

Shibata C, et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer : a case report. J Med Case Rep. 2019 ; 13 : 168. PMID : 31153385

 

P.512 掲載の参考文献

Kang K, et al. Paraneoplastic encephalitis and enteric neuropathy associated with anti-Hu antibody in a patient following immune-checkpoint inhibitor therapy. J Immunother. 2020 ; 43 : 165-168. PMID : 32195750

 

Appelbaum J, et al. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab : a case report. J Immunother Cancer. 2018 ; 6 : 82. PMID : 30170630

 

P.513 掲載の参考文献

Farid S, et al. Immune-checkpoint inhibitor-induced Fanconi syndrome. Cureus. 2020 ; 12 : e7686. PMID : 32431966

 

P.514 掲載の参考文献

Johncilla M, et al. Morphological spectrum of immune check-point ihibitor therapy-associated gastritis. Histopathology. 2020 ; 76 : 531-539. PMID : 31692018

 

P.515 掲載の参考文献

Deligiorgi MV, et al. Parathyroid hormone related protein (PTHrP) -mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. Int Immunopharmacol. 2019 ; 77 : 105942. PMID : 31699669

 

P.516 掲載の参考文献

Parker JS, et al. Corneal ulceration associated with nivolumab use. Am J Ophthalmol Case Rep. 2019 ; 14-26-27. PMID : 30815619

 

Weng CC, et al. Corneal melting in a case undergoing treatment with pembrolizumab. Clin Exp Optom. 2020 ; 103 : 379-381. PMID : 31692096

 

P.517 掲載の参考文献

Bedrose S, et al. A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma. AACE Clin Case Rep. 2020 ; 6 : e40-e45. PMID : 32524008

 

Haddad N, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2020 ; 182 : 477-480. PMID : 31077337

 

P.518 掲載の参考文献

Fadel F, et al. Anti-CTLA4 antibody-induced lupus nehritis. N Engl J Med. 2009 ; 361 : 211-212. PMID : 19587352

 

P.520 掲載の参考文献

Shimada T, et al. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord. 2020 ; 37 : 101447. PMID : 31655267

 

P.521 掲載の参考文献

Sagiv O, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg. 2019 ; 35 : 50-52. PMID : 29927883

 

P.522 掲載の参考文献

Eshet Y, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors : a case-control study. Cancer Immunol Res. 2018 ; 6 : 1453-1458. PMID : 30275274

 

Prasanna T, et al. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy. 2018 ; 10 : 171-175. PMID : 29370723

 

P.524 掲載の参考文献

Ravi V, et al. Neutrophilic dermatoses as adverse effects of checkpoint inhibitors : A review. Dermatol Ther. 2019 ; 32 : e13074. PMID : 31444856

 

P.525 掲載の参考文献

Thomas M, et al. Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol. 2018 ; 136 : 553-556. PMID : 29677240

 

P.526 掲載の参考文献

Willegers T, et al. Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab : a case report. J Immunother. 2020 ; 43 : 93-94. PMID : 32011418

 

Hamada S, et al. Bilateral vocal cord paralysis : pembrolizumab-induced delayed-onset toxicity in a patient with lung adenocarcinoma. J Thorac Oncol. 2018 ; 13 : e257-e259. PMID : 30467049

 

P.527 掲載の参考文献

Yoshida S, et al. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a melanoma patient. Clin Exp Dermatol. 2020 ; 45 : 908-911. PMID : 32394515

 

Gambichler T, et al. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy. 2020 ; 12 : 439-444. PMID : 32308086

 

P.528 掲載の参考文献

Sibille A, et al. Granulomatosis with polyangiitis in a patient on programmed death-1 inhibitor for advanced non-small-cell lung cancer. Front Oncol. 2019 ; 9 : 478. PMID : 31245290

 

Nabel CS, et al. Anti-PD-1 immunotherapy-induced flare of a known underlying relapsing vasculitis mimicking recurrent cancer. Oncologist. 2019 ; 24 : 1013-1021. PMID : 31088979

 

書評を投稿する